免疫功能低下人群的深部与播散性皮肤癣菌感染:系统综述
该系统综述纳入1954—2025年96项研究、134例经组织病理和真菌培养确诊的深部皮肤癣菌病患者,排除Majocchi肉芽肿。红色毛癣菌最常见,获得性和原发性免疫缺陷增加风险,24例出现系统播散,常伴淋巴结肿大。特比萘芬和伊曲康唑已用于治疗,多重耐药和长期治疗是潜在问题。
要点
- 免疫低下患者可出现深部皮肤癣菌感染并系统播散,应提高警惕。
- 红色毛癣菌是最常见分离病原,诊断需组织病理和真菌培养确认。
- 特比萘芬和伊曲康唑已用于治疗,多重耐药需关注。
核心结论
- 免疫功能低下人群的皮肤癣菌感染可能变为侵袭性和播散性,检测和早期治疗不应忽视。
研究设计与样本
- 2025年6月开展的系统综述,纳入1954—2025年96项研究、134例经组织病理检查和真菌培养确诊的深部皮肤癣菌病患者,排除Majocchi肉芽肿。
主要发现
- 21世纪以来报告数量明显增加,但诊断仍具挑战性。
- 红色毛癣菌是最常分离到的病原。
- 获得性免疫缺陷(如肾移植受者)和原发性免疫缺陷(如CARD9、STAT3突变)增加深部皮肤癣菌病风险。
- 24例报告系统播散,常伴淋巴结肿大,最常见为腋窝和腹股沟淋巴结感染,也有骨、肺和脑感染报告。
关键数值与推荐
- 特比萘芬125-1000 mg/天和伊曲康唑100-400 mg/天,辅以外用抗真菌药和手术干预,已用于深部皮肤癣菌病。
- 新型三唑类(伏立康唑、泊沙康唑)的使用应遵循抗真菌药物管理原则和治疗药物监测建议。
临床怎么用
- 对免疫低下患者应警惕皮肤癣菌感染侵袭和播散的可能,及时检测并早期治疗。
- 治疗需考虑延长或终身用药,并关注多重耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dermatophytes-a group of obligate keratinophilic fungi that infect the skin, hair and nails-represent the most common cause of fungal infections worldwide. In immunocompromised individuals, a growing body of literature has documented rare instances of dermatophyte infections of the dermis and subcutaneous tissue, which can lead to deep dermatophytosis with systemic dissemination and pseudomycetoma as secondary complications. OBJECTIVES: To assess patient characteristics, risk factors, diagnostic evidence and treatment options for deep dermatophytosis. METHODS: A systematic review was conducted in June 2025 to identify patients presenting with deep dermatophytosis of the glabrous skin; all cases were validated by confirmatory testing per histopathologic examination and fungal culture. Majocchi's granuloma diagnoses were excluded. RESULTS: The search yielded 96 studies (1954-2025) documenting 134 patients. The number of reports has notably increased since the 21st century; however, diagnosis remains challenging due to possible dermatophyte adaptation in the dermal/subcutaneous environment. Trichophyton rubrum is the most frequently isolated pathogen. Acquired immunodeficiencies (e.g. renal transplant recipients) and primary immunodeficiencies (e.g. CARD9, STAT3 mutations) elevate the risk of deep dermatophytosis. Systemic dissemination, often accompanied by lymphadenopathy, was reported in 24 patients, with the most common being infection of the axillary and inguinal lymph nodes. Infections of the bones, lungs, and brain were also reported. Terbinafine (125-1000 mg/day) and itraconazole (100-400 mg/day), with adjunctive topical antifungals and surgical interventions, have been tried for deep dermatophytosis. The use of newer triazoles (voriconazole, posaconazole) should follow the principles of antifungal stewardship and therapeutic drug monitoring recommendations. Multidrug resistance is a potential concern in immunocompromised patients who will often require extended or lifelong treatment. CONCLUSIONS: Healthcare providers should be cognizant that dermatophytosis may become invasive and disseminated in immunocompromised populations. Testing and early treatment should not be overlooked in these patients.
引用
- Gupta AK, Wang T, Susmita, et al. Deep and disseminated dermatophytosis in immunocompromised populations-A systematic review. J Eur Acad Dermatol Venereol. 2025. PMID: 41104791. doi:10.1111/jdv.70115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。